Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-SCF
- Development stage
- Preclinical
- Lead developer
- Joben Bio-Medical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
AB-SCF is a supercritical fluid extract derived from adlay bran (*Coix lacryma-jobi* var. *ma-yuen*), developed by Joben Bio-Medical. It is being investigated for its potential as a botanical drug or functional food for the treatment of hyperlipidemia and metabolic disorders. The extract is rich in unsaturated fatty acids, specifically oleic and linoleic acids, as well as ferulate phytostanol esters like 3-O-(trans-4-feruloyl)-β-sitostanol. Its mechanism of action involves the activation of the AMPK pathway (increasing p-AMPK) and lipoprotein lipase (LPL), while down-regulating fatty acid synthase (FAS), leading to reduced lipid accumulation, improved cholesterol metabolism, and increased bile acid excretion. Additionally, it exhibits antioxidant properties by modulating malondialdehyde (MDA) and glutathione (GSH) levels in hepatic tissues.
- Other names
- supercritical fluid extract of adlay branadlay bran supercritical fluid extract
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)FASN (Fatty acid synthase)LPL (Lipoprotein lipase)
Beyond the preview
Go deeper on AB-SCF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-SCF.